11 Erectile Dysfunction Clinical Trials in Madison, WI (2026)

Q: How do I join a clinical trial in Madison?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Madison research site will contact you.

Recruiting Erectile Dysfunction Studies in Madison

NCT06771830Recruiting

Evaluation of Pediatric eCART Implementation

This is a study comparing 3 years of retrospective data (pre-implementation) to 2 years of prospective data after the implementation of a pediatric version of Electronic Cardiac Arrest Risk Triage (pe...

Madison, WINA30,000 participantsUniversity of Wisconsin, Madison

View Study Details

NCT06581224Recruiting

Implementation of a Primary Hospital Provider (PHP) Team

The goal of this pragmatic clinical trial is to learn if it is possible to implement a Primary Hospital Provider (PHP) team that aims to improve continuity of care for patients who are frequently hosp...

Madison, WINA1,200 participantsUniversity of Wisconsin, Madison

View Study Details

NCT06722378Recruiting

A Trial to Improve Family Clinical Note Access and Outcomes for Hospitalized Children

This study will test if giving parents access to their child's medical notes on a bedside tablet: * helps them get more involved in their care * helps identify safety concerns Parents of hospitalize...

Madison, WINA630 participantsUniversity of Wisconsin, Madison

View Study Details

NCT05007782Recruiting

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS...

Madison, WIPHASE1416 participantsGilead Sciences

View Study Details

NCT06981156Recruiting

Evaluation of the Neurologic Assessment in Pediatric Neuro-Oncology (pNANO)

This study aims to investigate a neurologic exam scale to provide an objective and more standard way to assess tumor response in pediatric patients with brain and spinal cord tumors....

Madison, WI252 participantsUniversity of Wisconsin, Madison

View Study Details

NCT07205887Recruiting

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion...

Madison, WIPHASE2160 participantsEyeBiotech Ltd.

View Study Details

NCT06598800Recruiting

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and prelim...

Madison, WIPHASE1153 participantsBeOne Medicines

View Study Details

NCT06730347Recruiting

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be e...

Madison, WIPHASE280 participantsMacroGenics

View Study Details

NCT06975657Recruiting

Well-being Skills for Reentry

The goal of this clinical trial is to learn if a mindfulness skills training program has mental health benefits for people returning to the community following incarceration. The main questions it aim...

Madison, WINA60 participantsUniversity of Wisconsin, Madison

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Madison, WIPHASE120 participantsAdaptimmune

View Study Details

NCT06940440Recruiting

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carc...

Madison, WIPHASE19 participantsTuHURA Biosciences, Inc.

View Study Details

About Erectile Dysfunction Clinical Trials in Madison

Erectile dysfunction is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 30 million men in the U.S. and is often a sign of underlying cardiovascular disease. Treatment includes PDE5 inhibitors, vacuum devices, and penile implants.

There are currently 11 erectile dysfunction clinical trials recruiting participants in Madison, WI. These studies are seeking a combined 32,980 participants. Research is being sponsored by University of Wisconsin, Madison, Gilead Sciences, EyeBiotech Ltd. and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Erectile Dysfunction Clinical Trials in Madison — FAQ

Are there erectile dysfunction clinical trials in Madison?

Yes, there are 11 erectile dysfunction clinical trials currently recruiting in Madison, WI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Madison?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Madison research site will contact you about next steps.

Are clinical trials in Madison free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Madison studies also compensate for your time and travel.

What erectile dysfunction treatments are being tested?

The 11 active trials in Madison are testing new therapies including novel drugs, biologics, and treatment approaches for erectile dysfunction.

Data updated September 2, 2026 from ClinicalTrials.gov